The intra-vascular stent as a site-specific local drug delivery system

Drug Development and Industrial Pharmacy

Volumn 31, Issue 1, 2005, Pages 59-78

  Khan, Imran Ahmad ^a   Patravale, Vandana B ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Intra vascular stent; Restenosis; Site specific local drug delivery system; Stent coating

Indexed keywords

ANGIOPLASTY; CORONARY STENT; DRUG COATING; DRUG DELIVERY SYSTEM; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; STENT;

ANGIOPLASTY, BALLOON; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; EXCIPIENTS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHARMACEUTICAL PREPARATIONS; STENTS;

EID: 12844272817     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-44002     Document Type: Review

References (65)

1. Arya, M., Mostafid, H., Patel, H. R. H., Kellett, J. M., & Philp, T. (2001). The self-expanding metallic ureteric stent in the long-term management of benign ureteric strictures. 8JU International, 88, 339-342.
2. Bar, F. W., Van der Veen, F. H., Benzina, A., Habets, J., & Koole, L. H. (2000). New biocompatible polymer surface coating for stents results in a low neointimal response. Journal of Biomedical Materials Research, 52, 193-198.
3. Barry, J. J., & Palaqsis, M. Loading and Release of Water-Insoluble Drugs. US Patent 6,306,166, October 23, 2001.
4. Biro, S., Sigall, C. B., Fu, Y. M., Speir, E., Pastan, I., & Epstein, S. E. (1992). In vitro effect of recombinant toxin targeted to fibroblast growth factor receptor on rat vascular smooth muscle endothelial cells. Circulation Research, 71, 640-645.
5. Brim, D. S., & Grossman, W. (1998). Fauci, A. S., Wilson, J. D., Martin, J. B., Kasper, D. L., Harssser, S. L., Hango, D. L. (Eds.). Harrison's Principles of Internal Medicine (14th ed). Vol. 1. New York: Mc Graw Hill-(Health Professions Division), pp. 1376, 1377.
6. Chronos, N. A. F., Robinson, K. A., Kelly, A. B., Taylor, A., Yianni, J., King, S. B., III, Harker, L. A., & Hanson, S. R. (1995). Thromboresistant phosporylcholine coating for coronary stents. Circulation (Suppl. I), 92(8), I 685.
7. Colombo, A., & Tobis, J. (2000). Evaluation to our approach to stenting. Colombo, A., & Tobis, J. (Eds.). Techniques in Coronary Artery Stenting. London: Martin Dunitz Ltd., pp. 111-127.
8. Costa, M. A., Sabat, M., & van der Giessen, W. J. (1999). Late coronary occlusion after intra coronary brachytherapy. Circulation, 100, 789-792.
9. Drachman, D. E., Edelman, E. R., Seifert, P., Groothuis, A, R., Bornstein, D. A., Kamath, K. R., Palasis, M., Yang, D., Nott, S. H., & Rogers, C. (2000). Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. Journal of the American College of Cardiology, 36(7), 2325-2332.
10. Drug coated stent may prevent clogging of arteries. In Times of India. 20th March 2002.
11. Eberhard, G., Sigmund, S., Karl, E. H., Ralf, M., Lutz, B., Ulrich, G., & Mary, E. R. (2003). TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release poclitaxeleluting stent for de novo coronary lesions. Circulation, 107, 38-42.
12. Epstin, S. E., Sigall, C. B., Biro, S., Fu, Y. M., FitzGerald, O., & Pastan, I. (1991). Cytotoxic effect of recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation, 84, 778-787.
13. Eriksson, B. I., Kalebo, P., Ekman, S., Baur, M., Lindbratt, S., & Elach, D. (1995). The most effective and safe profilaxis of thrombo embolic complication in patient undergoing total hip replacement with recombinent hirudin (Revasc CBG 39393 Cibba). Circulation (Suppl. I), 92(8), I 868.
14. Fleser, A., Martel, R., Burchard, M., Voisine, P., & Leclerc, G. (1995). Antisence oligonucleotide transfiction: effect of angioplasty cholesterol linkage and target section on delivery efficiency. Circulation (Suppl. I), 92(8), I 670.
15. Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., Detre, K., Veltri, P. H. L., Ricci, D., Nobuyoshi, M., Cleman, M., Heuser, R., Almonmd, D., Teristein, P. S., Fish, R. O., Colombo, A., Brinker, J., Moses, J., Shaknovich, A., Hirshfeld, J., Bailey, S., Ellis, S., Randel, R. B. S., & Goldberg, S. (1994). A randomized comparison of coronary artery disease. New England Journal of Medicine, 331(8), 495-501.
16. Fishbein, I., Chorney, M., Rabinovich, L., Banai, S., Gati, I., & Golomb, G. (2000). Nanoparticulate delivery system of tryphosin for treatment of restinosis. Journal of Controlled Release, 65(1-2), 221-229.
17. Foils, J. D., Maalej, N., Kaeney, J. F., Jr., & Loscalzo, J. (1995). Coating plmaz-schatz stents with a unique NO donor renders them much less thrombogenic when placed in pig carotid arteries. Circulation (Suppl. I), 92(8), I 670.
18. Gunn, J., & Cumberland, D. (1999). Stent coating and local drug delivery: state of the art. European Heart Journal, 20(23), 1693-1700.
19. Hertzog, B. A., Thoms, C., & Sandor, M (1999). Cardiovascular drug delivery system. Edith, M., (Ed.). Encyclopedia of Controlled Drug Release. Vol. 1. New York: Jhon Wiely & Sons Inc., pp. 161-173.
20. Hidio, T., Kriji, I., Eisho, K., Kunihiko, K., Akiyoshi, K., Shigeo, M., Hidenori, K., Taskafumi, T., Seiichiro, M., & Hiromu, U. (2000). Initial six month result of biodegrable poly-L-lactic acid coronary stents in humans. Circulation, 102, 399-404.
21. Hossainy, Syed, F.A., & Chen, L. Porous Prosthesis and a Method of Depositing Substances Into the Pores. US Patent 6,287,628, September 11, 2001.
22. Jacob, A. K. (1999). Coronary stents - have they fulfilled their promise. New England Journal of Medicine, 341(26), 2005-2006.
23. Joshi, H. B., Newns, N., Stainthorpe, A., Macdonagh, R. P., Keeley, F. X., Jr. & Timoney, A. G. (2001). The development and validation of patient information booklet on uretric stent. BJU International, 88, 329-334.
24. Kataoka, T., Grube, E., Honda, Y., Morino, Y., Hur, S. H., Bonneau, H. N., Colombo, A., Mario, C. D., Guagliumi, G., Hauptmann, K. E., Pitney, M. R., Lansky, A. J., Stertzer, S. H., Yock, P. G., & Fitzgerald, P. J. (2002). 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the study to compare restenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation, 106, 1788-1793.
25. Keiser, J. A., & Uprichard, A. C. G. (1997). Restenosis: is there a pharmacologic fix in the pipe line. August, J. T. (Ed.). Advances in Pharmacology. 39, 313-351.
26. Latai, D., Maraz, J., Zerhu, P., Susani, M., & Merberger, M. (1994). Nitinol urethral stents: long term results in dog. Urological Research, 22, 295-300.
27. Lincoff, A. M., Furst, J. G., Ellis, S. G., Tuch, R. J., & Topol, E. J. (1997). Sustained local drug delivery by a novel intravasculareluting stent to prevent restinosis in the porcine coronary injury model. Journal of the American College of Cardiology, 29(4), 808-816.
28. Mak, K. H., Belli, G., Ellis, S. G., & Moliterno, D. J. (1996). Sub-acute stent thrombosis: evolving issue and current concept. Journal of the American College of Cardiology, 27, 494-503.
29. Makkar, R. R., Eigler, N. L., Nakamura, M., Litvack, F. I., Badimon, L., Jordan, R., Bramfitt, J., & Kaul, S. (1995). Monoclonal antibody to IIb/IIIa receptor (m7E3) is highly effective in inhibiting acute stent thrombosis. Circulation (Suppl. I), 92(8), I 685.
30. Mintz, G. S., Tinana, A., Hong, M. K., Lee, C. W., Kim, J. J., Fearnot, N. E., Park, S. W., Park, S. J., & Weissman, N. J. (2003). Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated stents: a serial volumetric intravascular ultrasound analysis from the asian paclitaxel-eluting stent clinical trial (ASPECT). Circulation, 108, 1295.
31. Montalescot, G., Choussat, R., & Collet, J. P. (2001). Glycoproteins IIb/IIIa receptors and primary stenting in acute myocardial infarction. European Heart Journal, Suppl 3(Suppl A), A3-A7.
32. Morice, M. C., Serruys, P. W., Sousa, J. E., Fajadet, J., Hayashi, E. B., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., Molinar, F., & Falotico, R. (2002). A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. New England Journal of Medicine, 346, 1773-1780.
33. Multanen, M., Talja, M., Hallanvuo, S., Siitonen, A., Valimaa, T., Tammela, T. L., Seppala, J., & Tormala, P. (2000). Bacterial adherence to oflaxacine blend poly lactone coated self-reinforced L- lactic acid polymer urological stent. BJU International, 86, 966-969.
34. Ortu, P., KaMuragila, G. M., Robert, G., Flotte, T. J., & Hasan, T. (1992). Photodynamic therapy of arteries: a novel approach for the treatment of experimental intimal hyperplasia. Circulation, 85, 1189-1196.
35. Pastore, C., Bacha, P., Pickering, J. G., Riessen, R., TakeShita, S., & Inser, J. M. (1993). Local and systemic delivery of DAB389EGF fusion toxin inhibits neointimal thickening in balloon-injured rat carotid. Circulation, 88(Supplement I), 1310.
36. Pickering, J. G., Bacha, P., Weir, L., Jekanowski, J., Nichols, J. C., & Isner, J. M. (1993). Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for epidermal growth factor receptor. Journal of Clinical Investigation, 97, 724-729.
37. Prout, G. R., Lin, C. W., & Benson, R. (1987). Photo therapy with hematoporphyrin derivative in treatment of superficial transitional cell carcinoma of the bladder. New England Journal of Medicine, 317, 1251-1255.
38. Ragheb, Anthony, O., Bates, B. L., Fearnot, N. E., Kozma, T. G., & Voorhees, W. D., III. Coated Implantable Medical Device. US Patent 6,299,604, October 9, 2001.
39. Range, H. P, Dale, M. M., & Ritter, J. M. (1995). Homeostasis and thrombosis. New York: Chirchill Livingston; pp. 331-350.
40. Regon, J. W (1998). Biotechnology and drug discovery. In: Delgado, J. N., William, A. R. (Eds.). Wilson and Gisvold's Textbook of Organic Medicinal Chemistry (10th ed.) New York: Lippincott, 139-152.
41. Riesen, R., & Isner, J. M. (1994). Prospects for site specific delivery of pharmacological and molecular therapies. Journal of the American College of Cardiology, 23(5), 1234-1244.
42. Ross, R. (1993). Pathogenesis of atherosclerosis: a prospective for 1990's. Nature, 362(29), 801-803.
43. Rox, S. P., Tschopp, T. B., & Kirchhofer, D. (1995). A monoclonal anti tissue factors antibody and nepsaginin a thrombotic inhibitor are more antithrombotic than heparin in arterial thrombosis. Circulation (Suppl. I), 92(8), I 685.
44. Roy, S., Baijal, S. S., Ishiguchi, T., Hirose, M., Fukatsu, H., Itoh, S., Sakuma, S., & Kasai, K. (1992). Esophageal stenting with a self-expandable metallic device: a preliminary study. Nagoya Journal of Medical Science, 54, 59-66.
45. Sadat, T., Morisseau, D., & Ross, A. (1993). Electron beam sterilization of heterogeneous medical devices. Radiation Physics and Chemistry, 42, 491-494.
46. Scott, N. A., Robinson, K. A., Nunes, G. L., Thomas, C. N., Viel, K., King, S. B., III, Harker, L. A., Rowland, S. M., Juman, I., Cipolla, G. D., & Hanson, S. R. (1995). Comparison of thrombogenicity of stainless steel and tantalum coronary stent. American Heart Journal, 129(5), 866-872.
47. Serruys, P. W., Hout, B. V., Bonnier, H., Legrand, V., Garcia, E., Macaya, C., Sousa, E., Giessen, W. V., Colombo, A., Seasbra-Gomes, R., Kiemenej, F., Ruygrok, P., Ormiston, J., Emanuelsson, H., Fajadet, J., Haude, M., Klugmann, S., & Morel, M. A. (1998). Randomized comparison of implantation of heparin coated stents with balloon angioplasty inspected patients with coronary artery disease (Benstent II). Lancet, 252, 495-501.
48. Serruys, W. P., & Kutryk, M. J. B. (Eds.). (2000). Handbook of Coronary Stents (3rd ed). London: Martin Dunitz Ltd.
49. Serruys, W. P., De Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., Emanuelsson, H., Marco, J., Legrand, V., Matertne, P., Belardi, J., Sigwart, U., Colombo, A., Goy, J. J., Heuvel, P., Jaun, D., & Morel, M. A. (1994). Compression of balloon expendable stent implantation with coronary angioplasty in patients with coronary artery disease. New England Journal of Medicine, 331(8), 495-501.
50. Sigwart, U., Puel, J., Mirkovitch, V., Joffre, F., & Kappenberger, L. (1987). Intra vascular stent prevent occlusion and retenosis after translumenal angioplasty. New England Journal of Medicine, 370(12), 701-706.
51. Spear, J. R., Serur, J., Shropshire, D., & Paulin, S. (1983). Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative. Journal of Clinical Investigation, 71 395-399.
52. Suzuki, T., Hayase, M., Hibi, K., Hosokawa, H., Yokoya, K., Fitzerland, P. J., Yock, P. G., Cooke, J. P., Suzuki, T., & Yeung, A. C. (2002). Effect of local delivery of L-aspargine on in-stent restinosis in humans. American Journal of Cardiology, 89, 360-367.
53. Swanson, N., Hogrefe, K., Javed, Q., & Gershlick, A. H. (2003a). In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents. International Journal of Cardiology, 92(2-3), 247-251.
54. Swanson, N., Hogrefe, K., Javed, Q., Malik, N., & Gershlick, A. H. (2003b). Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia. Journal of Invasive Cardiology, 15(12), 688-692.
55. th Ed; Thomas, C. L., Ed.; E.A. David Company: Philadelphia, 1978.
56. Toppl, E. J. (1994). Caveats about elective coronary stenting. New England Journal of Medicine, 331(8), 539-541.
57. Tuch, R. J. Blood Contacting Medical Device and Method. US Patent 5,865,814, February 2, 1999.
58. van Beuskeom, H. M. M., & Vander Giessen, W. J. (2000). Coronary stent coatings (Appendix E). Serruys, P. W., Kutryk, M. J. B. (Eds.). Handbook of Coronary Stents (3rd ed). London: Martin Dunitz Ltd., pp. 403-419.
59. Von Langenhore, G., Kutryk, M. J. B., & Surruys, P. W. (2000). Pharmacological adjacent to coronary stenting, the case of stent thrombosis (Appendix D). Serruys, P. W., Kutryk, M. J. B. (Eds.). Handbook of Coronary Stents (3rd ed.) London: Martin Dunitz Ltd., pp. 155-401.
60. Wang, A. G., Gunn, A. C., Ku, P., & Kathy, M. (1995). Relative efficay of venous thrombosis. Circulation (Suppl. I), 92(8), I 686.
61. Wu, Steven, Z., Harish, Millare, S., & Guruwiyia, Judy, Implantable Medical Device Having Protruding Surface Structures for Drug Delivery and Cover Attachment. US Patent 6,254,632, July 3, 2001.
62. Yang, D., Stanslaski, J. L., Wang, L., & Smith, S. R. Stent Coating. US Patent 6,258,121, July 10, 2001.
63. Zhong, & Sheng-P, P. Stents with Hybrid Coating for Medical Devices. US Patent 6,231,600, May 15, 2001.
64. Zhong, S. P. Method of Providing a Substrate with a Bio-Active/ Biocompatible Coating. US Patent 5,869,127, February 9, 1999.
65. Zider, J. P., Mohammad, S. F., Culp, S. C., Brott, B. C., Phillips, H. R., & Stack, R. S. (1993). In vitro thrombogenicity analysis of a new bioabsorbable, balloon expandable endovascular stent. Journal of the American College of Cardiology, 28(2), A 483. (Abstracts).